- cafead   Sep 06, 2019 at 10:22: AM
via Welcome to your weekly roundup of approaching clinical readouts. In the fourth quarter Obseva will see data from the first of two phase III trials of its gonadotropin-releasing hormone (GnRH) antagonist linzagolix in uterine fibroids.
article source
article source